miércoles, 20 de mayo de 2020

Recombinant protein produces neutralizing COVID-19 antibodies in primate model

Medical News | Medical Articles

Recombinant protein produces neutralizing COVID-19 antibodies in primate model

News Medical - Medical & Life Sciences
FacebookTwitterVimeo
 
 Antibodies 
 The latest antibodies news from News Medical 
 VHH Antibodies (Nanobodies) Advantages and LimitationsSARS-CoV-2 Specific and Neutralizing Antibodies

Sino Biological launched new antibodies against SARS-CoV-2. These two mouse mAbs are SARS-CoV-2 specific, with strong neutralizing activities and no cross-reactivity with SARS-CoV, and other common coronaviruses. And Sino Biological also launched a chimeric antibody specifically recognizing the S2 domain of SARS-CoV-2.

Find Out More
 
 
  KeysightAntibody Innovation Lab Service
 
Supporting drug development, including testing for SARS-CoV-2 drug candidates, ACROBiosystems provides a range of services including antibody screening, antibody characterizations, consistency, evaluation and anti-idiotypic bridging ELISA/pharmacokinetics development.
 
Read More
 
 
   Recombinant protein produces neutralizing COVID-19 antibodies in primate modelRecombinant protein produces neutralizing COVID-19 antibodies in primate model
 
A new study reports the induction of high levels of neutralizing antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus causing the current pandemic of COVID-19. This promising finding was reported on the preprint server bioRxiv on April 2020.
 
 Study shows human monoclonal antibodies can effectively neutralize SARS-CoV-2
 
Study shows human monoclonal antibodies can effectively neutralize SARS-CoV-2US researchers have published a proof of concept on the efficacy of human monoclonal antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in laboratory conditions.
 
 
 More cancer patients could benefit from CAR T-cell therapy, Moffitt study suggests
 
More cancer patients could benefit from CAR T-cell therapy, Moffitt study suggestsChimeric antigen receptor T-cell therapy, or CAR T, has become a game changer for lymphoma and leukemia patients who have relapsed or become resistant to previous treatments.
 
 
 Accelerating Antibody Discovery with Next-Generation Single-Cell Analysis
 
Accelerating Antibody Discovery with Next-Generation Single-Cell AnalysisAccelerating antibody discovery using picodroplet technology for single cell analysis to condense discovery times down to 1-2 days.
 
 
 Researchers discover new type of antigen-presenting immune cell
 
Researchers discover new type of antigen-presenting immune cellWith a discovery that could rewrite the immunology textbooks, an international group of scientists, identified a new type of antigen-presenting immune cell.
 
 
Website: www.news-medical.net
Email: info@news-medical.net
Telephone: +44 (0)161 457 7150
AZoNetwork UK Ltd.
NEO, 4th Floor
9 Charlotte Street, Manchester
M1 4ET, UK

No hay comentarios:

Publicar un comentario